Vancomycin for MRSA

Waitlist Available · 18+ · All Sexes · Hamilton, Canada

This study is evaluating whether continuous infusion of vancomycin is associated with less nephrotoxicity than intermittent dosing.

See full description

About the trial for MRSA

Treatment Groups

This trial involves 2 different treatments. Vancomycin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved


This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Adult patients with serious MRSA infections based on culture results including bacteremia, pneumonia, pleural space infection, central nervous system infection, bone infection, septic arthritis, prosthetic joint infection, and deep abscess
Enrollment within 4 days from date of MRSA culture collection
Patient either currently not on vancomycin or has received vancomycin for 4 days or less
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 28 days
Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 28 days.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Vancomycin will improve 1 primary outcome and 4 secondary outcomes in patients with MRSA. Measurement will happen over the course of 28 days.

All cause mortality
Clinical failure
Clinical failure based on infectious diseases physician's clinical judgment requiring switch from intravenous vancomycin to another anti-MRSA antibiotic therapy
Need for renal replacement therapy
Need for renal replacement therapy for any reason while on vancomycin
Vancomycin induced nephrotoxicity
Serum creatinine will be measured at enrolment as well as on day 1, 3, 5, 7, 14, 21 and 28. Nephrotoxicity is defined as an increase in serum creatinine by ≥44.2mmol/L or 50% since starting vancomycin compared to baseline. This increase in creatinine needs to occur while the patients is on vancomycin or within 7 days of discontinuation of vancomycin in order to be classified as vancomycin induced nephrotoxicity.
Microbiologic failure
Microbiologic failure based on demonstration of MRSA on repeated culture from the original sterile site (blood, lung, cerebral spinal fluid, bone, joint, peri-prosthetic joint, deep musculoskeletal tissue)

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for mrsa?

Staphylococcal wound infections are treated with antibiotics. Methicillin-resistant Staphylococcus aureus (MRSA) may not be effectively treated by antibiotics alone. Once a MRSA infection is suspected, antibiotics are no longer effective, and a surgical debridement and closure of the wound is necessary to eradicate the MRSA infection.

Anonymous Patient Answer

What causes mrsa?

The main cause of MRSA infection is the presence of the organism in the nasal mucosa. When nasal mucosa becomes inflamed, the bacteria are able to survive and multiply in the host's body. MRSA is usually spread through breaches in mucous membranes and contact with objects that contain the organism. When MRSA bacteria infect the skin, they can stay there for hours or even days and are easily spread. In the community, MRSA may be spread through saliva on teeth from people in close contact.

Anonymous Patient Answer

How many people get mrsa a year in the United States?

Approximately 10 million Americans have had a hospital-acquired staphylococcal infection each year. In contrast to skin infection, this review shows that the number of infections per patient is much higher than per patient for gastrointestinal infections.

Anonymous Patient Answer

What is mrsa?

MRSA is an opportunistic human pathogene that can cause serious illnesses in susceptible hosts. It is responsible for about 55 percent of hospital infections among the immunocompromised, and can be found in a variety of settings and conditions. Many studies on MRSA have been conducted to better understand the biology of this microorganism and its potential hazards to human health. However, it is only recently that MRSA had entered the research agenda. This article describes the microbiology, pathogenesis, and epidemiology of MRSA and its importance in medicine and healthcare.

Anonymous Patient Answer

What are the signs of mrsa?

Signs of MRSA, and the risks associated with MRSA, include increased frequency of skin lesions, such as boils, abscesses, eczema, and gangrene. Additionally, MRSA infections may be related to the spread of infection from the skin to the bloodstream. MRSA can also cross the blood-brain barrier into the brain where it may cause brain damage or infection. Lastly, MRSA is often spread through an infected catheter.

Anonymous Patient Answer

Can mrsa be cured?

Without further research, there is currently no way to cure MRSA. However, with current treatments, significant outcomes have been demonstrated in trials such as VOCAER trial. However, further research is necessary to develop more effective and more targeted antibiotics.

Anonymous Patient Answer

Does mrsa run in families?

Because our study demonstrates an association between MRSA carriage and S. aureus carrier status, we recommend a systematic screening of family members of MRSA carriers to detect carriers early and offer appropriate treatment.

Anonymous Patient Answer

What does vancomycin usually treat?

In this case, all we can give our patients is vancomycin for life, although we use a different approach to treatment because we acknowledge that the emergence of vancomycin resistance has increased.

Anonymous Patient Answer

What is the average age someone gets mrsa?

The age range of individuals being treated in the United States is 15.7 to 49.2 years, with an average age of 31.0 years. Infected males are more prone to having serious complications. Males are more likely than females to have complicated mrsa infections. Children infected with MRSA are younger than those infected with S. aureus. When MRSA is the sole pathogen found, males, ages 15 and over, have more severe disease compared with female and younger patients. Infected children with mrsa are more prone to complications. M. uber septicemicus is more common in males and adults over the age of 50 years. M.

Anonymous Patient Answer

How does vancomycin work?

Vancomycin is capable of inactivating virtually all strains of gram positive pathogens including MRSA. It is probably the most active of all penicillins known in the USA, and is routinely considered as the drug of choice for MRSA infections. While there is a long history of use of vancomycin, there is no clear evidence of its efficacy against MRSA. It may be more effective against MRSA strains that express vancomycin resistance genes, which is a relatively infrequent occurrence. Another possible explanation for inconsistencies in its efficacy might be the low potency of vancomycin against MRSA. Thus, more research on this compound and other antibacterial agents and their efficacy on MRSA must be conducted.

Anonymous Patient Answer

What are the latest developments in vancomycin for therapeutic use?

Pharmacokinetic and pharmacodynamic properties are being improved by increasing the oral bioavailability of this drug. It is the oral bioavailability of a drug that is a key indicator of its therapeutic efficacy, and the oral bioavailability of vancomycin is being increased by improving its dissolution and absorption from the gastrointestinal tract.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for MRSA by sharing your contact details with the study coordinator.